Purpose Sepsis, an intractable clinical syndrome, is often accompanied by severe vascular endothelial injury and barrier dysfunction. Previous evidence has shown that the endogenous repair mechanism of damaged vascular endothelium requires the proliferation of local endothelial cells (ECs), but processes of re-endothelialization and angiogenesis after endothelial injury are also affected by bone marrow-derived endothelial progenitor cells (EPCs). EPC mobilization has been linked to the mechanism of vascular endothelial repair in various chronic diseases. However, the potential value of EPC mobilization in the treatment of sepsis has not been explored. Methods Literature review was done to summarize the mobilization mechanism of EPC and to describe the cytokines and treatments related to EPC mobilization. Additionally, we summarize what is known about the mechanisms of endothelial damage and repair in sepsis. Results During sepsis, many endotoxins and inflammatory factors can damage ECs, resulting in increased vascular permeability and microcirculatory disorders. EPCs can serve as a source of ECs. Increasing evidence suggests that various cytokines and medicines can induce EPC mobilization. Conclusion EPC mobilization plays an important role in endothelial repair; this may guide the discovery of novel methods to treat sepsis.
Introduction
Sepsis is a potentially life-threatening complication of an infection and one of most the intractable medical syndromes, characterized by decreased vascular permeability and the massive release of inflammatory mediators [1] . Sepsis occurs when chemicals released in the bloodstream to fight an infection trigger inflammation throughout the body, causing a cascade of changes that damage multiple organ systems and can result in death [2] . Even with significant improvement in modern clinical treatment, there has been no significant decrease in the morbidity and mortality of sepsis [3] . The pathophysiological process of sepsis is complex, and vascular endothelial cells (ECs) play an important role. During sepsis, many endotoxins and inflammatory factors can stimulate vascular ECs to undergo morphological changes, apoptosis, and the destruction of intercellular connections, resulting in increased vascular permeability, thrombosis, and microcirculatory disorders [1, 4] . Due to the intimate contact of vessels and solid organs, the destruction of vascular ECs is closely related to organ dysfunction [5] . If there are only few desquamating cells as a result of damage, basement membrane coverage may be maintained through the proliferation and migration of surrounding ECs [6] . Although the potential proliferation of mature ECs is limited, endothelial progenitor cells (EPCs) can serve as a source of additional ECs [5] .
EPCs are heterogeneous population of cells capable of specific differentiation into ECs [7] . Although the pathway of EPC mobilization is unclear, there is sufficient evidence that EPCs can significantly promote endothelial repair by bone marrow (BM) mobilization or by exogenous transplantation to ischemic tissue. EPCs injected into ischemic animal models promoted neovascularization, and intravascular infusion of EPCs improved the prognosis of patients with acute myocardial infarction (AMI) [8] . Exogenous EPC transplantation has also been found to have positive effects on animal models of sepsis [9, 10] . EPCs derived from BM mediate the process of re-endothelialization after vascular injury in multiple steps of mobilization, chemotaxis, homing, proliferation, and differentiation [11, 12] . The mobilization of EPCs is the initial step of the process, and is heavily regulated. EPCs have a high proliferation potential, allowing these cells to be directly recruited to an injury site and then differentiate into mature ECs [13] . EPCs secrete many angiogenic factors and promote the proliferation, survival, and migration of mature ECs and other peripheral EPCs, thus promoting overall angiogenesis and vasculogenesis [13, 14] . EPCs also participate in the response to a damaged endothelium by the release of exosomes [2] .
Various cytokines and medicines can induce EPC mobilization [5, [15] [16] [17] , most studies have focused on treatments of tumor and chronic cardiovascular disease, with only few studies of sepsis, limiting the development of sepsis treatment. In this review, we discuss the latest developments in mobilization mechanisms of EPCs and summarize relevant cytokines and medicines. Finally, we discuss the mechanisms of vascular endothelium injury and repair in sepsis and important directions for future studies of these processes.
EPC mobilization in sepsis

Mechanisms of EPC mobilization
EPCs mainly reside within the BM and are rarely found in peripheral blood. When the EPCs in BM are stimulated by various factors, they migrate to the peripheral blood, a process called EPC mobilization [18] . The mobilization of EPCs is complex and not fully understood, which can be realized by a single factor potentially acting in multiple ways or coordinated by multiple factors. Generally, EPCs remain inactive in the BM microenvironment (stem cell niche), which is composed of fibroblasts, osteoblasts, and ECs [19] . EPCs are bound to VCAM-1 on the surface of bone marrow stromal cells (BMSC) by integrin (e.g. α4β1 and β3) [18] . Multiple cytokines and enzymes directly or indirectly promote the release of EPCs [16, 18, [20] [21] [22] (Fig. 1 ).
The change of EPC quantity in sepsis
EPCs are very rare in normal adult peripheral blood, present at a concentration of only about 0.2-0.42/4 ml blood [23] . However, the amount of EPCs changes significantly during sepsis. The course of sepsis is significantly correlated with the degree of EPC damage, and EPC can predict the prognosis of patients with severe sepsis. Kung et al. measured EPCs in the peripheral blood of 101 patients with sepsis and found that the level of EPCs in the severe sepsis group was significantly higher than that in the healthy controls [24] . Another study found that the circulating EPCs (cEPCs) levels in sepsis patients were significantly higher than the levels in non-sepsis patients and healthy controls, and survivors had significantly higher levels of cEPCs than non-survivors [25] . In contrast, Cribbs et al. reported significantly lower EPC levels in sepsis patients than in non-sepsis patients and healthy controls [8] . The peripheral blood EPC level of healthy volunteers dropped to the lowest point 6 h after lipopolysaccharide (LPS) infusion [26] . Differences in outcomes may be due to differences in patient inclusion criteria, blood test time, EPC count, and cell culture methods.
EPC and pro-angiogenic factors in sepsis
The change in EPCs in patients with sepsis may be part of an in vivo strategy to limit vascular damage by inducing endothelial repair mechanisms. Another possibility is that damage to endothelial cells may cause the rapid release of several proangiogenic factors. Various pro-angiogenic factors promote angiogenesis and can also play an important role in sepsis. During sepsis, ischemic tissue releases a variety of cytokines, including VEGF and SDF-1, which play an important role in vascular repair [3, 27] . And there is increased production and secretion of VEGF in various cells such as immune cells, ECs, and platelets. VEGF levels have been correlated with disease severity. In severe sepsis, patients with low VEGF levels are more likely to have organ dysfunction [28, 29] . SDF-1 is considered the most important chemokine stimulating EPC mobilization, and high local SDF-1 level contributes to the recruitment and retention of EPCs at the injury site [30] . SDF-1 can be rapidly upregulated in response to a series of stimuli such as inflammatory factors, hypoxia, and altered mechanical forces [31] . Through animal experiments, Fan et al. found that SDF-1α increased the number of cEPC in sepsis groups, increased IL-10 synthesis of macrophages, inhibited pulmonary vascular leakage, reduced liver and kidney damage, and improved endothelial cell function and reduced inflammatory reaction by upregulation of micRNA-126 and micRNA-125b expression [10] . HIF-1, a key mediator of cellular responses to hypoxic microenvironments, regulates SDF-1 expression. Recently, a prospective randomized clinical trial protocol was proposed to investigate the levels of circulating In the hypoxia state, the expression of various EPC-mobilizing cytokines is increased by hypoxia-inducible factor-1(HIF-1), including VEGF, SDF-1, MCP-1, and erythropoietin (EPO). These cytokines stimulate the release of nitric oxide (NO) through the PI3K/AKT/eNOS signaling channel, NO further promotes the expression of matrix met alloproteinase-9 (MMP-9). MMP-9 is a key regulatory factor of EPC mobilization. MMP-9 induces the release of soluble Kit ligand (skitL) from membrane-bound Kit ligand (mKitL). Both skitL and mKitL can competitively bind to c-kit receptors on the surface of EPCs, thereby weakening the interaction between EPCs and bone marrow stromal cells (BMSC). Neutrophil elastase and cathepsin G are largely stored in neutrophil cytoplasmic azurophilic granules. These proteases are released into the extracellular environment at inflammatory sites. G-CSF promotes the release of proteases and participates in the mobilization of EPC through multiple pathways as follows. First, protease can cleave integrin on the surface of EPC. Second, protease can cleave VCAM-1 on the surface of BMSC and prevent EPCs binding to BMSC through α4β1. Third, protease can synergize with MMP9 to degrade SDF-1 in the stromal niche and form a concentration gradient with high SDF-1 level in peripheral blood. Under the action of the concentration gradient, EPCs are driven into peripheral circulation stem cells, HIF-1, and SDF-1, in patients with sepsis after abdominal surgery and to explore their correlation [32] .
The injection of VEGF and SDF-1 increased EPC mobilization and improved survival in sepsis mice, and the injection of anti-VEGF and anti-SDF-1 was associated with a significant decrease in survival. Serum VEGF, SDF-1, and Ang-2 levels in preterm infants with sepsis were found to be higher than the control non-sepsis group [33] . This result was also verified in ICU patients with sepsis and acute renal dysfunction: increased endotoxin content promoted EPC mobilization and reduced proliferation via a mechanism related to the increased release of angiogenic agents such as VEGF, SDF-1, and Ang-2 [34] .
Other cytokines associated with EPC mobilization
Multiple other cytokines, such as bFGF (also known as FGF-2) [35] and hepatocyte growth factor (HGF) [36] have been shown to promote EPC mobilization and participate in the progression of sepsis. Blocking of the bFGF receptor FGFR signal by SSR128129E (a special antagonist of FGFR) can reduce the mobilization of EPCs in a tumor growth model [35] , further demonstrating the role of bFGF in EPC mobilization. In vivo experiments in mice showed that lung injury induced by LPS was significantly reduced in the treatment group that received mesenchymal stem cells (MSCs) with the FGF-2 gene (MSCs-FGF2) compared to the group treated with MSCs alone. The experiment also showed that FGF-2 promotes the proliferation of lung epithelial cells and the repair of lung tissue damage [37] . HGF is another multifunctional cytokine that regulates the growth, movement, and morphogenesis of multiple cells. Animal experiments showed that exogenous HGF mobilize EPCs and promote angiogenesis through the NOX2-ROS-Jak2/Jnk pathway [36] . HGF can also promote the proliferation and migration of EPCs. Serum HGF levels are elevated in patients with sepsis, which helps protect against endotoxin-induced organ dysfunction [38] . In septic mouse models injected with a lethal dose of LPS, recombinant HGF therapy has numerous merits, such as anti-apoptosis of hepatocyte and inhibition of hepatic dysfunction, leading to the inhibition of hepatic dysfunction. Strikingly, 75% of the septic mice survived after HGF injection, while the mice without HGF treatment all died of severe hepatic failure within 8 h after septic challenge. HGF also plays an anti-thrombotic role in sepsis [39] . In addition, TGF-β, GM-CSF, and G-CSF have been shown to be involved in EPC mobilization [20, 40, 41] .
Medicines that induce EPC mobilization and their role in sepsis
Both in vitro and in vivo studies have shown that EPC mobilization is regulated by external interventions and endogenous cytokines, including diet (consumption of green tea, a Mediterranean diet, or moderate amounts of wine) [42] , lifestyle (aerobic exercise, weight loss, and smoking cessation) [17] , and pharmacotherapy. Pharmacotherapy studies indirectly showed that EPCs can participate in endothelial repair in pathological condition [7] (Table 1 ). Multiple medicines have been found to reduce organ damage and reduce mortality in sepsis models, and if the action mechanism is related to the promotion of EPC mobilization is an important direction of research into sepsis treatment.
Statins
Statins are commonly used to reduce biosynthetic cholesterol in the liver. In addition to reducing serum cholesterol levels and slowing the progression of atherosclerosis, statins can increase NO bioavailability through the PI3 K/ Akt pathway, promoting EPC mobilization and accelerating endothelial recovery [43] . A randomized controlled study showed that patients pretreated with rosuvastatin had less myocardial damage after coronary surgery than those treated with a placebo. The authors also found increased cEPCs and high-sensitivity C-reactive protein (hsCRP) in the pharmacotherapy group [44] . Statins upregulated the expression of CXCR4 and promoted homing and neovascularization of EPCs in ischemic tissues [45] .
A number of retrospective cohort trials have shown that statins play an active role in the prevention and treatment of sepsis. In sepsis, statins protect vascular endothelium and reduce inflammatory damage, including downregulation of TLR-4, inhibition of NF-κB, and reduction of EC apoptosis [46] . Statins can prevent cognitive decline after sepsis by reverse sepsis-related neuroinflammation and microvascular dysfunction [47] . However, few randomized controlled trials have demonstrated the positive effects of statins on sepsis, so statins are not routinely used to treat sepsis.
ACEI and ARB
Angiotensin-converting enzyme inhibitors (ACEI) are used to treat hypertension by inhibiting the biosynthesis of Ang II. Several lines of evidence indicate that ACEI has pleiotropic effects on the cardiovascular system [48] , including regulation of the number and function of EPCs. ACEI increases the mobilization of EPCs by increasing levels of circulating SDF-1α and reducing SDF-1α levels in BM [17] . Investigators showed that after perindopril treatment in the diabetic rat model of AMI, the expression of VEGF in peripheral blood was increased [49] . The researchers speculated that activation of the VEGF/Akt/ eNOS signaling pathway may be one of the mechanisms by which ACEI promotes EPC mobilization. Angiotensin receptor blocker (ARB) is a medicine that is commonly used for hypertension treatment. Some data suggest that irbesartan can increase EPC mobilization and inhibit the release of circulating microparticles (MPs, vascular endothelial injury markers) in the atherosclerosis hamster model [50] . However, the exact mechanism is unclear.
The renin-angiotensin aldosterone system (RAAS) is essential to regulate fluid balance and blood pressure. Previous studies have shown that organ damage in sepsis is related to the activation of the RAAS, and inhibition of RAAS with ACEI or ARB could protect against EC damage and organ failure [51] . Candesartan can improve renal function, cardiac output and survival of septic animal models. In addition, continuous infusion of enalapril can reduce endothelial injury and protect against ALI [52] .
EPO
EPO, a glycoprotein produced mainly by the kidneys, can promote angiogenesis by promoting ECs proliferation and migration [16] . Darbepoetin-α can increase the mobilization, proliferation and differentiation of EPCs in patients with renal anemia, and EPO stimulates NO production by the action of eNOS [53] . Two clinical studies showed that EPO promoted EPC mobilization in patients with ischemic stroke and acute myocardial infarction [54, 55] . This conclusion was subsequently verified in animal experiments, which found that EPO mediates hypoxic-related EPC mobilization in a Nox2-dependent manner [56] . The PI3 K/Akt pathway may participate in this process [40] .
EPO levels are increased in the cecal ligation and puncture (CLP) model, reducing pulmonary, renal, and brain [70] eNOS and VEGF↑ Rivaroxaban Mouse Diabetes [71] damages [57] . The kidney protection by EPO is related to the reduction of renal microvascular damage. EPO promotes the expression of EPO receptor and VEGF in sepsis, and also reduces the expression of HIF-1α, i-NOS, and NF-κB [58] .
Endothelial injury and repair in sepsis
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [59] . In patients with severe sepsis and septic shock, microcirculation disorders, functional capillary density reduction, and vascular heterogeneity increase are observed [3] . Researchers have recognized that microvascular endothelial barrier dysfunction and the destruction of microcirculation integrity are key factors in organ failure and should be targets for treatment [60] . The mechanisms of sepsis-related vascular endothelial injury and repair are complex [60] [61] [62] [63] [64] (Fig. 2) . Until now, there remains no effective treatment for sepsis. The clinical prognosis of patients with sepsis depends on the degree of endothelial injury, and the repair of the vascular endothelium associated with severe infection partially depends on the processes of mature ECs proliferation, migration, and angiogenesis [65] . Previous studies reported The mechanisms of sepsis-related vascular permeability increase are complex, and existing evidence suggests that direct ECs injury, apoptosis, ECs cytoskeletal remodeling, and disruption of intercellular junctions may contribute. In sepsis,the NF-κB-to-AP-1 switch may be one of the protective mechanisms to ensure transition from endothelial injury to repair. VEGF and SDF-1 are upregulated in ischemic tissues. VEGF activates cdc-42 and Rac1 by binding to VEGFR2 on the surface of ECs, and mediates the formation of filopodia and lamellipodia, eventually leading to EC migration and the formation of new blood vessels. SDF-1 increases FoxM1 expres-sion in ECs by activating GPCR-dependent p110γPI3 K. FoxM1 is involved in the transcriptional regulation of cell cycle progression genes, mediates the G1/S and G2/M transition, and facilitates EC proliferation. In addition to proliferation and migration, the repair of the vascular endothelium requires the reconstruction of the intercellular connections of ECs. FoxM1 helps to reanneal adheren junctions through the transcriptional control of β-catenin. In addition, those EPCs that are mobilized from bone marrow to peripheral blood can differentiate into ECs, promote the repair of damaged endothelium, and participate in the angiogenesis of ischemic tissue the migration of adjacent ECs after mechanical arterial endothelial denudation, but the role of ECs in restoring vascular barrier function after organ damage remains unclear [66] . Animal studies showed that SDF-1, MMP-9, VEGF, TNF-α, and NO levels in sepsis groups were significantly increased compared with normal control groups [12] . The mobilization of VEGF and SDF-1 for EPCs in septic patients and animal models is described above. FGF is another growth factor with extensive physiological functions. One of its receptors, FGFR1, plays an important role in bone development and metabolism. Targeted deletion of Fgfr1 in osteoblasts enhances the level of EPCs in circulation in an endotoxemia model and is related to the upregulation of SDF-1 [19] .
Some amino acids can also promote the mobilization of EPCs in sepsis. In mice with sepsis induced by CLP, intravenous glutamine (GLN) promotes the mobilization of EPCs by increasing the release of SDF-1, VEGF, and NO [5] . GLN improves vascular function by regulating the balance of Ang-Tie2 axis, reducing inflammatory response and lung tissue damage. Dietary GLN supplementation also enhanced the mobilization of EPCs in limb ischemia of diabetic mice [67] . l-arginine (Arg) is a non-essential amino acid that is also the sole substrate of nitric oxide synthase (NOS) and a precursor of NO synthesis. Intravenous Arg alleviated lung injury in a sepsis model, maintained the homeostasis of the Angpt/ Tie-2 axis (a recognized vascular steady-state tag), increased circulating proangiogenic cell mobilization, and relieved organ damage [12] . Studies have found that neuromuscular electrical stimulation can also significantly enhance the mobilization of cEPC and improve the prognosis of patients with sepsis, possibly through hormone release [68] .
Conclusion
The activation, injury, and dysfunction of vascular ECs are key links in the development of sepsis and should be the focus of treatment. Previous systemic treatment of sepsis has mainly relied on the administration of antibiotics and fluid perfusion. There are two main types of treatment measures targeting ECs, blocking factors leading to endothelial injury or targeting ECs directly by inhibiting EC adhesion, antagonizing EC apoptosis, or blocking EC signal transduction. The main purpose of these strategies is to stop the development of damaged vascular endothelium and delay disease progression, but few studies have explored how to promote repair after injury. Some cytokines, including VEGF and SDF-1, promote EPC mobilization and improve survival in sepsis, and additional cytokines and medicine have been found to play similar roles in other inflammation-related diseases. If the cytokines and medicine that promote EPC mobilization in other inflammatory-related diseases also contribute to sepsis, this may guide the discovery of novel methods to treat sepsis and improve the prognosis of this complex syndrome. Overall, a deeper understanding of the mechanisms of vascular endothelial injury and repair in sepsis can help us prevent and treat this disease more effectively.
